Apollomics, Inc. (NASDAQ:APLMW – Get Free Report) was the recipient of a large increase in short interest in the month of March. As of March 31st, there was short interest totalling 52,500 shares, an increase of 16.7% from the March 15th total of 45,000 shares. Based on an average daily volume of 17,900 shares, the days-to-cover ratio is currently 2.9 days.
Apollomics Price Performance
APLMW traded up $0.01 during trading hours on Tuesday, reaching $0.03. 720 shares of the company’s stock traded hands, compared to its average volume of 21,131. The firm has a 50-day moving average price of $0.03 and a 200 day moving average price of $0.03. Apollomics has a 52-week low of $0.01 and a 52-week high of $0.13.
Hedge Funds Weigh In On Apollomics
Large investors have recently bought and sold shares of the business. Ionic Capital Management LLC purchased a new position in Apollomics during the 1st quarter valued at $30,000. Shaolin Capital Management LLC purchased a new position in Apollomics during the 1st quarter valued at $33,000. Finally, ATW Spac Management LLC purchased a new position in Apollomics during the 1st quarter valued at $39,000.
Apollomics Company Profile
Apollomics, Inc, a biotechnology company, engages in the discovery and development of mono and combination oncology therapies to harness the immune system and target specific molecular pathways to inhibit cancer. Its pipeline consists of various development-stage assets, including novel and humanized monoclonal antibodies that restore the body's immune system to recognize and kill cancer cells, and targeted therapies against uncontrolled growth signaling pathways.
See Also
- Five stocks we like better than Apollomics
- CD Calculator: Certificate of Deposit Calculator
- Silicon Motion Proves That AI in Motion Stays in Motion
- 3 Fintech Stocks With Good 2021 Prospects
- Undervalued UnitedHealth Group Won’t Be For Long
- How to Most Effectively Use the MarketBeat Earnings Screener
- The 5 Stocks Most Sold By Insiders This Year
Receive News & Ratings for Apollomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apollomics and related companies with MarketBeat.com's FREE daily email newsletter.